Increased risk of purge system malfunction after Impella 5.0 replacement: a case series.
Impella 5.0
Long-term use
Prognosis
System malfunction
Journal
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs
ISSN: 1619-0904
Titre abrégé: J Artif Organs
Pays: Japan
ID NLM: 9815648
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
19
01
2022
accepted:
02
05
2022
pubmed:
17
5
2022
medline:
3
3
2023
entrez:
16
5
2022
Statut:
ppublish
Résumé
The Impella 5.0 is an axial-flow percutaneous ventricular assist device used in patients with cardiogenic shock. Although the recommended period of use is 10 days or less, weaning can be delayed because of ongoing hemodynamic instability. In clinical practice, this device sometimes malfunctions during long-term management with heparin and must be replaced; however, the relationship between the duration of support with the initial and replacement Impella 5.0 and the changes in value of the purge system has not been fully elucidated. From July 2018 to May 2021, Impella 5.0 was implanted and used for more than 10 days in 11 patients at our institution. Four patients required Impella replacement because of device malfunction and the second Impella had purge system malfunction in all cases. The second Impella was used for a significantly shorter time than the first Impella (p = 0016). We calculated the ratio of purge pressure to purge flow rate and found that the ratio exceeded 50 mm Hg/mL/h in all cases with purge system malfunction. In conclusion, it is important to construct a treatment strategy considering the duration of use, because the risk of purge system malfunction is high after replaced Impella 5.0.
Identifiants
pubmed: 35575950
doi: 10.1007/s10047-022-01337-0
pii: 10.1007/s10047-022-01337-0
doi:
Substances chimiques
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-83Informations de copyright
© 2022. The Japanese Society for Artificial Organs.
Références
Batsides G, Massaro J, Cheung A, Soltesz E, Ramzy D, Anderson MB. Outcomes of Impella 5.0 in cardiogenic shock: a systematic review and meta-analysis. Innovations (Phila). 2018;13:254–60.
doi: 10.1097/IMI.0000000000000535
pubmed: 30142110
Schibilsky D, Lausberg H, Haller C, Lenglinger M, Woernle B, Haeberle H, Rosenberger P, Walker T, Schlensak C. Impella 5.0 support in INTERMACS II cardiogenic shock patients using right and left axillary artery access. Artif Organs. 2015;39:660–3.
doi: 10.1111/aor.12529
pubmed: 26147682
Tarabichi S, Ikegami H, Russo MJ, Lee LY, Lemaire A. The role of the axillary Impella 5.0 device on patients with acute cardiogenic shock. J Cardiothorac Surg. 2020;15:1–5.
doi: 10.1186/s13019-020-01251-7
Bertoglio L, Katsarou M, Scandroglio M, Bertoldi L, Chiesa R, Pappalardo F. Surgical transaxillary placement of the Impella 5.0 ventricular assist device. J Card Surg. 2019;34:92–8.
doi: 10.1111/jocs.13978
pubmed: 30625252
Nelson DW, Sundararajan S, Klein E, Joyce LD, Durham LA, Joyce DL, Mohammed AA. Sustained use of the Impella 5.0 heart pump enables bridge to clinical decisions in 34 patients. Texas Hear Inst J. 2021;48:1–8.
Mastroianni C, Bouabdallaoui N, Leprince P, Lebreton G. Short-term mechanical circulatory support with the Impella 5.0 device for cardiogenic shock at La Pitié-Salpêtrière. Eur Hear J Acute Cardiovasc Care. 2017;6:87–92.
doi: 10.1177/2048872616633877
Lima B, Kale P, Gonzalez-Stawinski GV, Kuiper JJ, Carey S, Hall SA. Effectiveness and safety of the impella 5.0 as a bridge to cardiac transplantation or durable left ventricular assist device. Am J Cardiol. 2016;117:1622–8.
doi: 10.1016/j.amjcard.2016.02.038
pubmed: 27061705
Arnett DM, Lee JC, Harms MA, Kearney KE, Ramos M, Smith BM, Anderson EC, Tayal R, McCabe JM. Caliber and fitness of the axillary artery as a conduit for large-bore cardiovascular procedures. Catheter Cardiovasc Interv. 2018;91:150–6.
doi: 10.1002/ccd.27416
pubmed: 29130612
Said A, Sayed L. Percutaneous thrombectomy of Impella-associated iliac artery thrombosis using the FlowTriever system. Clin Case Rep. 2020;8:2645–9.
doi: 10.1002/ccr3.3226
pubmed: 33363797
pmcid: 7752490